Impact of socioeconomic status on biologics utilization in rheumatoid arthritis: revealing inequalities and healthcare efficiency
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: This cross-sectional study aimed to investigate biologics treatment disparities in rheumatoid arthritis (RA) patients based on socioeconomic status (SES). Methods: Data from the KOrean Observational Study Network for Arthritis (KORONA) database were analyzed to assess various factors associated with SES, health behaviors, and biologics use. Logistic regression and structured equation modeling (SEM) were utilized for data analysis. Results: Among 5,077 RA patients included, 393 (7.7%) patients were identified as biologics users. Within the entire cohort, 31.8% of the participants were in the low-income and low-education groups, and 39.3% of the participants were in the high-income and high-education groups. Despite the patients with low income or low education experienced higher disease activity at diagnosis, had more comorbidities, exhibited higher medication compliance, underwent more check-ups, and had more hospital admissions than their counterparts, the odds of patients with low-income receiving biologics were 34% lower (adjusted odds ratio = 0.76, 95% confidence interval: 0.60–0.96, p = 0.021) after adjustment for demographics and comorbidities. SEM and pathway analyses confirmed the negative impact of low SES on biologics use. Conclusions: The findings suggest that SES plays a significant role in biologics use among RA patients, indicating potential healthcare inefficiencies for low SES patients. Moreover, adverse healthcare habits negatively affect biologics use in RA patients. The study highlights the importance of considering socioeconomic factors while discussing biologics use and promoting equitable access to biologics for optimal RA management.
Abstract
Background/Aims: This cross-sectional study aimed to investigate biologics treatment disparities in rheumatoid arthritis (RA) patients based on socioeconomic status (SES). Methods: Data from the KOrean Observational Study Network for Arthritis (KORONA) database were analyzed to assess various factors associated with SES, health behaviors, and biologics use. Logistic regression and structured equation modeling (SEM) were utilized for data analysis. Results: Among 5,077 RA patients included, 393 (7.7%) patients were identified as biologics users. Within the entire cohort, 31.8% of the participants were in the low-income and low-education groups, and 39.3% of the participants were in the high-income and high-education groups. Despite the patients with low income or low education experienced higher disease activity at diagnosis, had more comorbidities, exhibited higher medication compliance, underwent more check-ups, and had more hospital admissions than their counterparts, the odds of patients with low-income receiving biologics were 34% lower (adjusted odds ratio = 0.76, 95% confidence interval: 0.60–0.96, p = 0.021) after adjustment for demographics and comorbidities. SEM and pathway analyses confirmed the negative impact of low SES on biologics use. Conclusions: The findings suggest that SES plays a significant role in biologics use among RA patients, indicating potential healthcare inefficiencies for low SES patients. Moreover, adverse healthcare habits negatively affect biologics use in RA patients. The study highlights the importance of considering socioeconomic factors while discussing biologics use and promoting equitable access to biologics for optimal RA management.
참고문헌 (27)
- Breedveld FC, "Understanding emerging treatment paradigms in rheumatoid arthritis", Arthritis Res Ther, 13(Suppl 1), pp.S3~ (2011)
- Malaviya AP, "Rheumatoid arthritis and the era of biologic therapy", Inflammopharmacology, 20, pp.59~69 (2012)
- Tatangelo M, "Association of patient, prescriber, and region with the initiation of first prescription of biologic disease-modifying antirheumatic drug among older patients with rheumatoid arthritis and identical health insurance coverage", JAMA Netw Open, 2, pp.e1917053~ (2019)
- Schmajuk G, "Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans", JAMA, 305, pp.480~486 (2011)
- Codreanu C, "Area of residence and socioeconomic factors reduce access to biologics for rheumatoid arthritis patients in romania", Biomed Res Int, 2018, pp.7458361~ (2018)
- Molina E, "Association of socioeconomic status with treatment delays, disease activity, joint damage, and disability in rheumatoid arthritis", Arthritis Care Res(Hoboken), 67, pp.940~946 (2015)
- Margaretten M, "Socioeconomic determinants of disability and depression in patients with rheumatoid arthritis", Arthritis Care Res(Hoboken), 63, pp.240~246 (2011)
- Jacobi CE, "Impact of socioeconomic status on the course of rheumatoid arthritis and on related use of health care services", Arthritis Rheum, 49, pp.567~573 (2003)
- DeWitt EM, "Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States : an analysis using a large observational data bank", Clin Ther, 31, pp.1871~1880 (2009)
- Camacho EM, "Association between socioeconomic status, learned helplessness, and disease outcome in patients with inflammatory polyarthritis", Arthritis Care Res(Hoboken), 64, pp.1225~1232 (2012)
- Kotyla PJ, "Bimodal function of anti-TNF treatment : shall we be concerned about anti-TNF treatment in patients with rheumatoid arthritis and heart failure?", Int J Mol Sci, 19, pp.1739~ (2018)
- Dixon WG, "Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy : results from the British Society for Rheumatology Biologics Register", Arthritis Rheum, 54, pp.2368~2376 (2006)
- Alder NE, "The role of psychosocial processes in explaining the gradient between socioeconomic status and health", Curr Dir Psychol Sci, 12, pp.119~123 (2003)
- Verstappen SMM, "The impact of socio-economic status in rheumatoid arthritis", Rheumatology(Oxford), 56, pp.1051~1052 (2017)
- Chiu H, "Under-reporting of socio-economic status in randomized control trials of biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis", Rheumatology(Oxford), 56, pp.660~661 (2017)
- Sung YK, "Korean Observational Study Network for Arthritis(KORONA) : establishment of a prospective multicenter cohort for rheumatoid arthritis in South Korea", Semin Arthritis Rheum, 41, pp.745~751 (2012)
- Arnett FC, "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis", Arthritis Rheum, 31, pp.315~324 (1988)
- Rothman KJ, "Concepts of interaction", Am J Epidemiol, 112, pp.467~470 (1980)
- Charlson ME, "A new method of classifying prognostic comorbidity in longitudinal studies : development and validation", J Chronic Dis, 40, pp.373~383 (1987)
- Dey M, "Association between social deprivation and disease activity in rheumatoid arthritis : a systematic literature review", RMD Open, 8, pp.e002058~ (2022)
- Bergstra SA, "Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide : results from the METEOR-registry", Ann Rheum Dis, 77, pp.1413~1420 (2018)
- Baek YH, "Trends in polypharmacy over 12 years and changes in its social gradients in South Korea", PLoS One, 13, pp.e0204018~ (2018)
- Kim JH, "Impact of health insurance status changes on healthcare utilisation patterns : a longitudinal cohort study in South Korea", BMJ Open, 6, pp.e009538~ (2016)
- Pampel FC, "Socioeconomic disparities in health behaviors", Annu Rev Sociol, 36, pp.349~370 (2010)
- Sriram S, "Effect of health insurance program for the poor on out-of-pocket inpatient care cost in India : evidence from a nationally representative cross-sectional survey", BMC Health Serv Res, 20, pp.839~ (2020)
- Kangovi S, "Understanding why patients of low socioeconomic status prefer hospitals over ambulatory care", Health Aff(Millwood), 32, pp.1196~1203 (2013)
- Kalkan A, "Factors influencing rheumatologists’ prescription of biological treatment in rheumatoid arthritis : an interview study", Implement Sci, 9, pp.153~ (2014)